ZOLADEX AstraZeneca Pty Ltd
Product name
ZOLADEX
Sponsor
Accepted date
Apr-2026
Active ingredients
goserelin
Summary of proposed indication
ZOLADEX (goserelin) is proposed as a treatment for early and advanced oestrogen receptor (ER)-positive breast cancer in women who have not yet gone through menopause or who are close to menopause.
Application type
C (new indication)
Publication date
Apr-2026